#read

Life sciences are a key feature of the 2026 Saxony Start-up Award

This year’s winners of the Saxony Start-up Award highlight a striking trend within Saxony’s innovation ecosystem. With Meliodays Medical GmbH named Start-up of the Year and DEMECAN GmbH named Scale-up of the Year, two of the three award-winning companies come from the life sciences and healthcare sectors. As a result, biotechnology and medical technology had a disproportionately strong influence on this year’s competition.
17/06/2026

Meliodays Medical is developing a hormone-free treatment for period pain. The active ingredient is designed to be released specifically within the uterus, providing a long-term treatment option for patients. DEMECAN produces pharmaceutical-grade medical cannabis in Saxony and covers the entire value chain from cultivation to delivery to pharmacies. The third award went to Oxaphil GmbH. The company develops functional polymers for applications in the pharmaceutical and cosmetics industries and translates research findings from Dresden University of Technology into industrial applications. A total of 116 start-up projects were submitted for the competition. For the first time, a prize was awarded for scale-ups in addition to the ‘Newcomer’ and ‘Start-up’ categories. The results highlight the growing importance of science-based spin-offs for Saxony as a centre of innovation. In particular, companies in the fields of biotechnology, life sciences and medical technology are increasingly becoming a defining feature of the regional start-up landscape.

Press release from the “Saxon State Ministry for Economic Affairs, Labour, Energy and Climate Protection” dated 17 June 2026

The above texts, or parts thereof, were automatically translated from the original language text using a translation system (DeepL API).
Despite careful machine processing, translation errors cannot be ruled out.

Click here to access the original content